{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:25:49Z","timestamp":1793665549742,"version":"4.5.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82103045"],"award-info":[{"award-number":["82103045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82000113"],"award-info":[{"award-number":["82000113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82103045"],"award-info":[{"award-number":["82103045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82000113"],"award-info":[{"award-number":["82000113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemotherapy-induced thrombocytopenia (CIT) is a common condition that frequently results in reduced chemotherapy dosages, postponed treatment, bleeding, and unfavorable oncological outcomes. At present, there is no clear suggestions for preventing or treating CIT. Thrombopoietin (TPO) replacement therapy has been invented and used to treat CIT to promote the production of megakaryocytes and stimulate the formation of platelets. However, this treatment is limited to the risk of immunogenicity and cancer progression. Therefore, an unmet need exists for exploring alternatives to TPO to address the clinical issue of CIT. Application of appropriate therapeutic drugs may be due to understanding the potential mechanisms of CIT. Studies have shown that chemotherapy significantly affects various cells in bone marrow (BM) microenvironment, reduces their ability to support normal hematopoiesis, and may lead to BM damage, including CIT in cancer patients. This review focuses on the epidemiology and treatment of cancer patients with CIT. We also introduce some recent progress to understand the cellular and molecular mechanisms of chemotherapy inhibiting normal hematopoiesis and causing thrombocytopenia.<\/jats:p>","DOI":"10.1007\/s12672-023-00616-3","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:02:56Z","timestamp":1674630176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Chemotherapy-induced thrombocytopenia: literature review"],"prefix":"10.1007","volume":"14","author":[{"given":"Ai","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"4","key":"616_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1078155210380293","volume":"17","author":"A Hitron","year":"2011","unstructured":"Hitron A, et al. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract. 2011;17(4):312\u20139. https:\/\/doi.org\/10.1177\/1078155210380293.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"616_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","volume":"28","author":"J Crawford","year":"2020","unstructured":"Crawford J, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2020;28(2):925\u201332. https:\/\/doi.org\/10.1007\/s00520-019-04875-1.","journal-title":"Support Care Cancer"},{"issue":"3","key":"616_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tracli.2018.06.004","volume":"25","author":"C Humbrecht","year":"2018","unstructured":"Humbrecht C, Kientz D, Gachet C. Platelet transfusion: current challenges. Transfus Clin Biol. 2018;25(3):151\u201364. https:\/\/doi.org\/10.1016\/j.tracli.2018.06.004.","journal-title":"Transfus Clin Biol"},{"issue":"Suppl 1","key":"616_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12959-016-0095-z","volume":"14","author":"K Kaushansky","year":"2016","unstructured":"Kaushansky K. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. Thromb J. 2016;14(Suppl 1):40. https:\/\/doi.org\/10.1186\/s12959-016-0095-z.","journal-title":"Thromb J"},{"key":"616_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev-pathol-012615-044414","volume":"11","author":"J Hoggatt","year":"2016","unstructured":"Hoggatt J, Kfoury Y, Scadden DT. Hematopoietic stem cell Niche in health and disease. Annu Rev Pathol. 2016;11:555\u201381. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044414.","journal-title":"Annu Rev Pathol"},{"issue":"Pt 2","key":"616_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","volume":"31","author":"Y Wu","year":"2009","unstructured":"Wu Y, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000\u20132007. Clin Ther. 2009;31(Pt 2):2416\u201332. https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.020.","journal-title":"Clin Ther"},{"issue":"1","key":"616_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","volume":"19","author":"D Weycker","year":"2019","unstructured":"Weycker D, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151. https:\/\/doi.org\/10.1186\/s12885-019-5354-5.","journal-title":"BMC Cancer"},{"issue":"4","key":"616_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1200\/jco.2001.19.4.1137","volume":"19","author":"LS Elting","year":"2001","unstructured":"Elting LS, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137\u201346. https:\/\/doi.org\/10.1200\/jco.2001.19.4.1137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"616_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.13595","volume":"106","author":"JL Shaw","year":"2021","unstructured":"Shaw JL, et al. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol. 2021;106(5):662\u201372. https:\/\/doi.org\/10.1111\/ejh.13595.","journal-title":"Eur J Haematol"},{"issue":"13","key":"616_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995\u20131008. https:\/\/doi.org\/10.1056\/NEJMra010501.","journal-title":"N Engl J Med"},{"issue":"5","key":"616_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","volume":"14","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437\u201348. https:\/\/doi.org\/10.1080\/17474086.2021.1924053.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"616_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","volume":"34","author":"MJ Ten Berg","year":"2011","unstructured":"Ten Berg MJ, et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study. Drug Saf. 2011;34(12):1151\u201360. https:\/\/doi.org\/10.2165\/11594310-000000000-00000.","journal-title":"Drug Saf"},{"issue":"4","key":"616_CR13","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282\u201394.","journal-title":"Oncology (Williston Park)"},{"issue":"11","key":"616_CR14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2015-01-623645","volume":"126","author":"H Cheng","year":"2015","unstructured":"Cheng H, et al. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126(11):1302\u201313. https:\/\/doi.org\/10.1182\/blood-2015-01-623645.","journal-title":"Blood"},{"issue":"2","key":"616_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2018","unstructured":"Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2018;7(2):265\u201373. https:\/\/doi.org\/10.21037\/apm.2017.11.01.","journal-title":"Ann Palliat Med"},{"key":"616_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3054","volume":"344","author":"K Ker","year":"2012","unstructured":"Ker K, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344: e3054. https:\/\/doi.org\/10.1136\/bmj.e3054.","journal-title":"BMJ."},{"issue":"26","key":"616_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/nejm199712253372602","volume":"337","author":"P Rebulla","year":"1997","unstructured":"Rebulla P, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto. N Engl J Med. 1997;337(26):1870\u20135. https:\/\/doi.org\/10.1056\/nejm199712253372602.","journal-title":"N Engl J Med."},{"issue":"7","key":"616_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","volume":"362","author":"SJ Slichter","year":"2010","unstructured":"Slichter SJ, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600\u201313. https:\/\/doi.org\/10.1056\/NEJMoa0904084.","journal-title":"N Engl J Med"},{"issue":"1","key":"616_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1537-2995.1999.39199116901.x","volume":"39","author":"TL Densmore","year":"1999","unstructured":"Densmore TL, et al. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39(1):103\u20136.","journal-title":"Transfusion"},{"issue":"26","key":"616_CR20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1056\/nejm199712253372601","volume":"337","author":"The Trial to Reduce Alloimmunization to Platelets Study Group","year":"1997","unstructured":"The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861\u20139. https:\/\/doi.org\/10.1056\/nejm199712253372601.","journal-title":"N Engl J Med."},{"issue":"9","key":"616_CR21","first-page":"3607","volume":"87","author":"I Tepler","year":"1996","unstructured":"Tepler I, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87(9):3607\u201314.","journal-title":"Blood"},{"issue":"11","key":"616_CR22","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1007\/s00520-019-04734-z","volume":"27","author":"NW Liu","year":"2019","unstructured":"Liu NW, et al. Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia. Support Care Cancer. 2019;27(11):4293\u20138. https:\/\/doi.org\/10.1007\/s00520-019-04734-z.","journal-title":"Support Care Cancer"},{"issue":"11","key":"616_CR23","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdm341","volume":"18","author":"CH Moskowitz","year":"2007","unstructured":"Moskowitz CH, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18(11):1842\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdm341.","journal-title":"Ann Oncol"},{"issue":"5","key":"616_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","volume":"132","author":"S Vadhan-Raj","year":"2000","unstructured":"Vadhan-Raj S, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132(5):364\u20138. https:\/\/doi.org\/10.7326\/0003-4819-132-5-200003070-00005.","journal-title":"Ann Intern Med"},{"issue":"12","key":"616_CR25","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.v98.12.3241","volume":"98","author":"J Li","year":"2001","unstructured":"Li J, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241\u20138. https:\/\/doi.org\/10.1182\/blood.v98.12.3241.","journal-title":"Blood"},{"issue":"4","key":"616_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","volume":"56","author":"J Bussel","year":"2019","unstructured":"Bussel J, et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019;56(4):262\u201378. https:\/\/doi.org\/10.1053\/j.seminhematol.2019.09.001.","journal-title":"Semin Hematol"},{"key":"616_CR27","doi-asserted-by":"publisher","first-page":"204062072091299","DOI":"10.1177\/2040620720912992","volume":"11","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992. https:\/\/doi.org\/10.1177\/2040620720912992.","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"616_CR28","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1613878.","journal-title":"N Engl J Med"},{"issue":"6","key":"616_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bjh.16658","volume":"190","author":"DT Mytych","year":"2020","unstructured":"Mytych DT, et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol. 2020;190(6):923\u201332. https:\/\/doi.org\/10.1111\/bjh.16658.","journal-title":"Br J Haematol"},{"issue":"1","key":"616_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12253-010-9276-4","volume":"17","author":"J Demeter","year":"2011","unstructured":"Demeter J, et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res. 2011;17(1):141\u20133. https:\/\/doi.org\/10.1007\/s12253-010-9276-4.","journal-title":"Pathol Oncol Res"},{"key":"616_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26473","author":"AE Jacobson","year":"2017","unstructured":"Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26473.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"616_CR32","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","volume":"103","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103(4):e169\u201372. https:\/\/doi.org\/10.3324\/haematol.2017.180166.","journal-title":"Haematologica"},{"issue":"5","key":"616_CR33","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00520-013-2074-2","volume":"22","author":"R Parameswaran","year":"2014","unstructured":"Parameswaran R, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217\u201322. https:\/\/doi.org\/10.1007\/s00520-013-2074-2.","journal-title":"Support Care Cancer"},{"issue":"31","key":"616_CR34","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1200\/jco.18.01931","volume":"37","author":"GA Soff","year":"2019","unstructured":"Soff GA, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol. 2019;37(31):2892\u20138. https:\/\/doi.org\/10.1200\/jco.18.01931.","journal-title":"J Clin Oncol"},{"issue":"4","key":"616_CR35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021;106(4):1148\u201357. https:\/\/doi.org\/10.3324\/haematol.2020.251900.","journal-title":"Haematologica"},{"issue":"10","key":"616_CR36","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","volume":"26","author":"A Kellum","year":"2010","unstructured":"Kellum A, et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010;26(10):2339\u201346. https:\/\/doi.org\/10.1185\/03007995.2010.510051.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"616_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/cam4.326","volume":"4","author":"ES Winer","year":"2015","unstructured":"Winer ES, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015;4(1):16\u201326. https:\/\/doi.org\/10.1002\/cam4.326.","journal-title":"Cancer Med"},{"issue":"6","key":"616_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","volume":"106","author":"ES Winer","year":"2017","unstructured":"Winer ES, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017;106(6):765\u201376. https:\/\/doi.org\/10.1007\/s12185-017-2319-9.","journal-title":"Int J Hematol"},{"issue":"25","key":"616_CR39","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel JB, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887\u201394. https:\/\/doi.org\/10.1182\/blood-2013-07-514398.","journal-title":"Blood"},{"issue":"3","key":"616_CR40","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/s2352-3026(22)00001-1","volume":"9","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022;9(3):e179\u201389. https:\/\/doi.org\/10.1016\/s2352-3026(22)00001-1.","journal-title":"Lancet Haematol"},{"issue":"5","key":"616_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1535-7163.mct-15-0775","volume":"15","author":"JE Bisi","year":"2016","unstructured":"Bisi JE, et al. Preclinical characterization of G1T28: a novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol Cancer Ther. 2016;15(5):783\u201393. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0775.","journal-title":"Mol Cancer Ther"},{"key":"616_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986","author":"S He","year":"2017","unstructured":"He S, et al. Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aal3986.","journal-title":"Sci Transl Med"},{"issue":"10","key":"616_CR43","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol. 2019;30(10):1613\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdz278.","journal-title":"Ann Oncol"},{"issue":"10","key":"616_CR44","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33453","volume":"148","author":"D Daniel","year":"2020","unstructured":"Daniel D, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2020;148(10):2557\u201370. https:\/\/doi.org\/10.1002\/ijc.33453.","journal-title":"Int J Cancer"},{"issue":"1","key":"616_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350\u201365. https:\/\/doi.org\/10.1007\/s12325-020-01538-0.","journal-title":"Adv Ther"},{"issue":"5","key":"616_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021;22(5):449\u201360. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010.","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"616_CR47","doi-asserted-by":"publisher","first-page":"Cd003407","DOI":"10.1002\/14651858.CD003407.pub5","volume":"12","author":"T Tonia","year":"2012","unstructured":"Tonia T, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):Cd003407. https:\/\/doi.org\/10.1002\/14651858.CD003407.pub5.","journal-title":"Cochrane Database Syst Rev."},{"key":"616_CR48","doi-asserted-by":"publisher","first-page":"135354","DOI":"10.1155\/2010\/135354","volume":"2010","author":"CL Erickson-Miller","year":"2010","unstructured":"Erickson-Miller CL, et al. Thrombopoietin receptor levels in tumor cell lines and primary tumors. J Oncol. 2010;2010:135354. https:\/\/doi.org\/10.1155\/2010\/135354.","journal-title":"J Oncol"},{"issue":"18","key":"616_CR49","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2016-04-711986","volume":"128","author":"PJ Rauch","year":"2016","unstructured":"Rauch PJ, et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood. 2016;128(18):2253\u20137. https:\/\/doi.org\/10.1182\/blood-2016-04-711986.","journal-title":"Blood"},{"issue":"25","key":"616_CR50","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","volume":"132","author":"M Dickinson","year":"2018","unstructured":"Dickinson M, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629\u201338. https:\/\/doi.org\/10.1182\/blood-2018-06-855221.","journal-title":"Blood"},{"key":"616_CR51","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/dddt.s299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, et al. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther. 2021;15:2243\u201368. https:\/\/doi.org\/10.2147\/dddt.s299591.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"616_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cell.2008.01.025","volume":"132","author":"SH Orkin","year":"2008","unstructured":"Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132(4):631\u201344. https:\/\/doi.org\/10.1016\/j.cell.2008.01.025.","journal-title":"Cell"},{"issue":"6774","key":"616_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/35004599","volume":"404","author":"K Akashi","year":"2000","unstructured":"Akashi K, et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404(6774):193\u20137. https:\/\/doi.org\/10.1038\/35004599.","journal-title":"Nature"},{"issue":"5","key":"616_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0092-8674(00)80453-5","volume":"91","author":"M Kondo","year":"1997","unstructured":"Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91(5):661\u201372.","journal-title":"Cell"},{"issue":"4","key":"616_CR55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood.V82.4.1092.1092","volume":"82","author":"J Lotem","year":"1993","unstructured":"Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 1993;82(4):1092\u20136.","journal-title":"Blood"},{"issue":"8","key":"616_CR56","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V91.8.2998.2998_2998_3006","volume":"91","author":"P Wlodarski","year":"1998","unstructured":"Wlodarski P, et al. Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood. 1998;91(8):2998\u20133006.","journal-title":"Blood"},{"issue":"12","key":"616_CR57","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.exphem.2003.08.014","volume":"31","author":"A Meng","year":"2003","unstructured":"Meng A, et al. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol. 2003;31(12):1348\u201356. https:\/\/doi.org\/10.1016\/j.exphem.2003.08.014.","journal-title":"Exp Hematol"},{"issue":"2","key":"616_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.stem.2010.06.014","volume":"7","author":"M Mohrin","year":"2010","unstructured":"Mohrin M, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010;7(2):174\u201385. https:\/\/doi.org\/10.1016\/j.stem.2010.06.014.","journal-title":"Cell Stem Cell"},{"issue":"17","key":"616_CR59","first-page":"5414","volume":"63","author":"A Meng","year":"2003","unstructured":"Meng A, et al. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 2003;63(17):5414\u20139.","journal-title":"Cancer Res"},{"issue":"10","key":"616_CR60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1593\/neo.08466","volume":"10","author":"B Das","year":"2008","unstructured":"Das B, et al. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia. 2008;10(10):1105\u201319. https:\/\/doi.org\/10.1593\/neo.08466.","journal-title":"Neoplasia"},{"issue":"17","key":"616_CR61","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.ejca.2003.07.002","volume":"39","author":"B Das","year":"2003","unstructured":"Das B, et al. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity implications in cancer chemotherapy. Eur J Cancer. 2003;39(17):2556\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2003.07.002.","journal-title":"Eur J Cancer."},{"issue":"7","key":"616_CR62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00204-004-0643-3","volume":"79","author":"AR Abd-Allah","year":"2005","unstructured":"Abd-Allah AR, et al. L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol. 2005;79(7):406\u201313. https:\/\/doi.org\/10.1007\/s00204-004-0643-3.","journal-title":"Arch Toxicol"},{"issue":"11","key":"616_CR63","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/psp4.12459","volume":"8","author":"C Fornari","year":"2019","unstructured":"Fornari C, et al. Quantifying drug-induced bone marrow toxicity using a novel haematopoiesis systems pharmacology model. CPT Pharmacometrics Syst Pharmacol. 2019;8(11):858\u201368. https:\/\/doi.org\/10.1002\/psp4.12459.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"616_CR64","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00280-015-2679-x","volume":"75","author":"K G\u00e9resi","year":"2015","unstructured":"G\u00e9resi K, et al. Myelotoxicity of carboplatin is increased in vivo in db\/db mice, the animal model of obesity-associated diabetes mellitus. Cancer Chemother Pharmacol. 2015;75(3):609\u201318. https:\/\/doi.org\/10.1007\/s00280-015-2679-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"616_CR65","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-s","volume":"31","author":"P Mauch","year":"1995","unstructured":"Mauch P, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1319\u201339. https:\/\/doi.org\/10.1016\/0360-3016(94)00430-s.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"616_CR66","first-page":"101","volume":"5","author":"NG Testa","year":"1985","unstructured":"Testa NG, Hendry JH, Molineux G. Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res. 1985;5(1):101\u201310.","journal-title":"Anticancer Res"},{"key":"616_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1995.tb31039.x","volume":"770","author":"GW Santos","year":"1995","unstructured":"Santos GW. Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Ann N Y Acad Sci. 1995;770:1\u20137. https:\/\/doi.org\/10.1111\/j.1749-6632.1995.tb31039.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"5","key":"616_CR68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3978\/j.issn.2218-676X.2013.07.03","volume":"2","author":"L Shao","year":"2013","unstructured":"Shao L, et al. Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. Transl Cancer Res. 2013;2(5):397\u2013411. https:\/\/doi.org\/10.3978\/j.issn.2218-676X.2013.07.03.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"616_CR69","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood.V92.6.1950","volume":"92","author":"R van Os","year":"1998","unstructured":"van Os R, et al. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood. 1998;92(6):1950\u20136.","journal-title":"Blood"},{"issue":"6","key":"616_CR70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/bf00685889","volume":"32","author":"RV Gardner","year":"1993","unstructured":"Gardner RV, et al. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol. 1993;32(6):450\u20134. https:\/\/doi.org\/10.1007\/bf00685889.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"616_CR71","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/blood.V72.4.1193.1193","volume":"72","author":"P Mauch","year":"1988","unstructured":"Mauch P, Rosenblatt M, Hellman S. Permanent loss in stem cell self renewal capacity following stress to the marrow. Blood. 1988;72(4):1193\u20136.","journal-title":"Blood"},{"issue":"9","key":"616_CR72","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.freeradbiomed.2012.02.007","volume":"52","author":"CM Diaz-Montero","year":"2012","unstructured":"Diaz-Montero CM, et al. The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. Free Radic Biol Med. 2012;52(9):1560\u20138. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.02.007.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"616_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-011-0872-1","volume":"94","author":"L Shao","year":"2011","unstructured":"Shao L, et al. Reactive oxygen species and hematopoietic stem cell senescence. Int J Hematol. 2011;94(1):24\u201332. https:\/\/doi.org\/10.1007\/s12185-011-0872-1.","journal-title":"Int J Hematol"},{"key":"616_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.freeradbiomed.2012.10.530","volume":"54","author":"H Zhang","year":"2013","unstructured":"Zhang H, et al. Resveratrol ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice. Free Radic Biol Med. 2013;54:40\u201350. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.10.530.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"616_CR75","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.3706","volume":"20","author":"M Zhao","year":"2014","unstructured":"Zhao M, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014;20(11):1321\u20136. https:\/\/doi.org\/10.1038\/nm.3706.","journal-title":"Nat Med"},{"issue":"3","key":"616_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.stem.2010.02.002","volume":"6","author":"GA Challen","year":"2010","unstructured":"Challen GA, et al. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell. 2010;6(3):265\u201378. https:\/\/doi.org\/10.1016\/j.stem.2010.02.002.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"616_CR77","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1634\/stemcells.2008-0219","volume":"26","author":"A Chabanon","year":"2008","unstructured":"Chabanon A, et al. A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence\/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin. Stem Cells. 2008;26(12):3150\u201361. https:\/\/doi.org\/10.1634\/stemcells.2008-0219.","journal-title":"Stem Cells"},{"issue":"11","key":"616_CR78","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","volume":"95","author":"J Pedersen-Bjergaard","year":"2000","unstructured":"Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95(11):3273\u20139.","journal-title":"Blood"},{"key":"616_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exphem.2017.12.010","volume":"60","author":"Y Gong","year":"2018","unstructured":"Gong Y, et al. Megakaryocyte-derived excessive transforming growth factor beta1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2018;60:40-46.e2. https:\/\/doi.org\/10.1016\/j.exphem.2017.12.010.","journal-title":"Exp Hematol"},{"issue":"8","key":"616_CR80","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1634\/stemcells.2004-0354","volume":"23","author":"L Wang","year":"2005","unstructured":"Wang L, et al. Activation of transforming growth factor-beta1\/p38\/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage. Stem Cells. 2005;23(8):1122\u201334. https:\/\/doi.org\/10.1634\/stemcells.2004-0354.","journal-title":"Stem Cells"},{"issue":"5","key":"616_CR81","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2013.08.007","volume":"154","author":"R Yamamoto","year":"2013","unstructured":"Yamamoto R, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell. 2013;154(5):1112\u201326. https:\/\/doi.org\/10.1016\/j.cell.2013.08.007.","journal-title":"Cell"},{"issue":"7470","key":"616_CR82","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12495","volume":"502","author":"A Sanjuan-Pla","year":"2013","unstructured":"Sanjuan-Pla A, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232\u20136. https:\/\/doi.org\/10.1038\/nature12495.","journal-title":"Nature"},{"issue":"2","key":"616_CR83","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1084\/jem.20131128","volume":"211","author":"JY Shin","year":"2014","unstructured":"Shin JY, et al. High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. J Exp Med. 2014;211(2):217\u201331. https:\/\/doi.org\/10.1084\/jem.20131128.","journal-title":"J Exp Med"},{"issue":"6","key":"616_CR84","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41556-020-0512-1","volume":"22","author":"F Dong","year":"2020","unstructured":"Dong F, et al. Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis. Nat Cell Biol. 2020;22(6):630\u20139. https:\/\/doi.org\/10.1038\/s41556-020-0512-1.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"616_CR85","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","volume":"166","author":"SK Quirk","year":"2015","unstructured":"Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015;166(5):412\u201324. https:\/\/doi.org\/10.1016\/j.trsl.2015.06.005.","journal-title":"Transl Res"},{"issue":"7382","key":"616_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10783","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457\u201362. https:\/\/doi.org\/10.1038\/nature10783.","journal-title":"Nature"},{"issue":"2","key":"616_CR87","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2004-11-4269","volume":"106","author":"HG Kopp","year":"2005","unstructured":"Kopp HG, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106(2):505\u201313. https:\/\/doi.org\/10.1182\/blood-2004-11-4269.","journal-title":"Blood"},{"issue":"3","key":"616_CR88","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.stem.2009.01.006","volume":"4","author":"AT Hooper","year":"2009","unstructured":"Hooper AT, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4(3):263\u201374. https:\/\/doi.org\/10.1016\/j.stem.2009.01.006.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"616_CR89","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/07357907.2020.1855353","volume":"39","author":"H Rafieemehr","year":"2021","unstructured":"Rafieemehr H, et al. Chemo\/radiotherapy-induced bone marrow niche alterations. Cancer Invest. 2021;39(2):180\u201394. https:\/\/doi.org\/10.1080\/07357907.2020.1855353.","journal-title":"Cancer Invest"},{"issue":"2","key":"616_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s8756-3282(02)00822-0","volume":"31","author":"JH Davies","year":"2002","unstructured":"Davies JH, et al. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy. Bone. 2002;31(2):319\u201326. https:\/\/doi.org\/10.1016\/s8756-3282(02)00822-0.","journal-title":"Bone"},{"issue":"5","key":"616_CR91","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s002230020039","volume":"70","author":"JH Davies","year":"2002","unstructured":"Davies JH, et al. In vitro effects of chemotherapeutic agents on human osteoblast-like cells. Calcif Tissue Int. 2002;70(5):408\u201315. https:\/\/doi.org\/10.1007\/s002230020039.","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"616_CR92","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/1097-0142(20011101)92:9<2419::aid-cncr1591>3.0.co;2-k","volume":"92","author":"A Banfi","year":"2001","unstructured":"Banfi A, et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer. 2001;92(9):2419\u201328. https:\/\/doi.org\/10.1002\/1097-0142(20011101)92:9%3c2419::aid-cncr1591%3e3.0.co;2-k.","journal-title":"Cancer"},{"issue":"12","key":"616_CR93","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.exphem.2011.08.009","volume":"39","author":"S Buttiglieri","year":"2011","unstructured":"Buttiglieri S, et al. The aging effect of chemotherapy on cultured human mesenchymal stem cells. Exp Hematol. 2011;39(12):1171\u201381. https:\/\/doi.org\/10.1016\/j.exphem.2011.08.009.","journal-title":"Exp Hematol"},{"issue":"8","key":"616_CR94","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ncb3570","volume":"19","author":"BO Zhou","year":"2017","unstructured":"Zhou BO, et al. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat Cell Biol. 2017;19(8):891\u2013903. https:\/\/doi.org\/10.1038\/ncb3570.","journal-title":"Nat Cell Biol"},{"issue":"7571","key":"616_CR95","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature15250","volume":"526","author":"M Acar","year":"2015","unstructured":"Acar M, et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature. 2015;526(7571):126\u201330. https:\/\/doi.org\/10.1038\/nature15250.","journal-title":"Nature"},{"issue":"1","key":"616_CR96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0002-9440(10)64518-x","volume":"157","author":"D Zucker-Franklin","year":"2000","unstructured":"Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol. 2000;157(1):69\u201374. https:\/\/doi.org\/10.1016\/s0002-9440(10)64518-x.","journal-title":"Am J Pathol"},{"issue":"1","key":"616_CR97","first-page":"15","volume":"15","author":"KM Young","year":"1989","unstructured":"Young KM. Localization of megakaryocytes in the bone marrow. Blood Cells. 1989;15(1):15\u201321.","journal-title":"Blood Cells"},{"issue":"1","key":"616_CR98","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nm973","volume":"10","author":"ST Avecilla","year":"2004","unstructured":"Avecilla ST, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10(1):64\u201371. https:\/\/doi.org\/10.1038\/nm973.","journal-title":"Nat Med"},{"issue":"6","key":"616_CR99","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","volume":"16","author":"PI Croucher","year":"2016","unstructured":"Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer. 2016;16(6):373\u201386. https:\/\/doi.org\/10.1038\/nrc.2016.44.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"616_CR100","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1038\/s41467-021-26556-6","volume":"12","author":"RKH Yip","year":"2021","unstructured":"Yip RKH, et al. Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis. Nat Commun. 2021;12(1):6920. https:\/\/doi.org\/10.1038\/s41467-021-26556-6.","journal-title":"Nat Commun"},{"issue":"2","key":"616_CR101","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21307\/immunohematology-2019-099","volume":"30","author":"BR Curtis","year":"2014","unstructured":"Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology. 2014;30(2):55\u201365.","journal-title":"Immunohematology"},{"issue":"6","key":"616_CR102","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","volume":"7","author":"RH Aster","year":"2009","unstructured":"Aster RH, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911\u20138. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03360.x.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"616_CR103","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jjco\/hyp035","volume":"39","author":"Y Kanemitsu","year":"2009","unstructured":"Kanemitsu Y, et al. A randomized phase II\/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 2009;39(6):406\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyp035.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"616_CR104","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4103\/0973-1482.154056","volume":"12","author":"GU Erdem","year":"2016","unstructured":"Erdem GU, et al. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509\u201314. https:\/\/doi.org\/10.4103\/0973-1482.154056.","journal-title":"J Cancer Res Ther"},{"issue":"5","key":"616_CR105","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1537-2995.2005.04373.x","volume":"45","author":"BM Taleghani","year":"2005","unstructured":"Taleghani BM, et al. Oxaliplatin-induced immune pancytopenia. Transfusion. 2005;45(5):704\u20138. https:\/\/doi.org\/10.1111\/j.1537-2995.2005.04373.x.","journal-title":"Transfusion"},{"issue":"3","key":"616_CR106","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.20516","volume":"81","author":"BR Curtis","year":"2006","unstructured":"Curtis BR, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006;81(3):193\u20138. https:\/\/doi.org\/10.1002\/ajh.20516.","journal-title":"Am J Hematol"},{"issue":"1","key":"616_CR107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000178163","volume":"76","author":"A Polyzos","year":"2009","unstructured":"Polyzos A, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1):36\u201341. https:\/\/doi.org\/10.1159\/000178163.","journal-title":"Oncology"},{"key":"616_CR108","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214593","author":"A Gao","year":"2019","unstructured":"Gao A, et al. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2018.214593.","journal-title":"Haematologica"},{"issue":"10","key":"616_CR109","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s2213-2600(16)30265-x","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania NA, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781\u201396. https:\/\/doi.org\/10.1016\/s2213-2600(16)30265-x.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"616_CR110","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/0008-5472.can-06-4303","volume":"67","author":"A Zeuner","year":"2007","unstructured":"Zeuner A, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007;67(10):4767\u201373. https:\/\/doi.org\/10.1158\/0008-5472.can-06-4303.","journal-title":"Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:32:08Z","timestamp":1674631928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00616-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"30 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declares no competing interest in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}